These findings raise the possibility that PKCα/β inhibition may provide a novel therapy to confer cardioprotection in ACS patients with hyperglycaemia, whilst preventing the risk of causing hypoglycaemia by glucose lowering interventions. Here, PRKCA is linked to Hypoglycemia.